Serum Angiopoetin-2 Levels in Pediatric Patients After Fontan Operation

• DOI: 10.1016/j.amjcard.2023.06.112
• Publication Date: 2023-07-21T02:51:12Z
• Authors: Keijiro Ibuki; Teruhiko Imamura; Hideyuki Nakaoka; Shinya Takarada; Mako Okabe; Sayaka Ozawa; Koichiro Kinugawa; Keiichi Hirono
• Keywords: Male; Angiopoietin-2; Heart Defects, Congenital; Inflammation; Treatment Outcome; Risk Factors; Child, Preschool; Humans; Child; Fontan Procedure; 3. Good health; Retrospective Studies

Angiopoietin-2 is associated with chronic inflammation and angiogenesis, but its activity after Fontan operation in pediatric patients remains uncertain. We compared serum angiopoietin-2 levels in pediatric patients after Fontan operation versus those with congenital heart disease as a control group. A total of 185 patients (median age 7 [3 to 12] years, 106 males) were included, consisting of 140 in the Fontan group and 45 in the control group. Serum angiopoietin-2 levels were significantly higher in the Fontan group (7,670 vs 2,351 pg/ml, p <0.001). In the Fontan group, a serum angiopoietin-2 level ≥3.9 of common logarithm was an independent risk factor for death or Fontan-related adverse events with an adjusted hazard ratio of 6.25 (95% confidence interval 1.64 to 23.9, p = 0.007). In preoperative variables, desaturation was independently associated with increased serum angiopoietin-2 levels after Fontan operation (p = 0.047). In conclusion, serum angiopoietin-2 levels were elevated in the pediatric phase after Fontan operation. In Fontan patients, a higher serum angiopoietin-2 level was an independent risk factor for death or Fontan-related adverse events. The clinical implication of measuring and monitoring serum angiopoietin-2 levels in this cohort requires further investigation.